Ani Pharmaceuticals (ANIP) Non Operating Income (2013 - 2026)

Ani Pharmaceuticals (ANIP) has 14 years of Non Operating Income data on file, last reported at -$3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 31.27% year-over-year to -$3.8 million; the trailing twelve-month figure through Mar 2026 stood at -$18.3 million (up 0.76% YoY), and the FY2025 full-year result was -$20.1 million, down 13.96% from the prior year.
• Non Operating Income advanced to -$3.8 million in Q1 2026, from -$4.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of -$2.3 million in Q3 2024 to a low of -$7.7 million in Q1 2023.
• A 5-year average of -$5.7 million and a median of -$5.7 million in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income slumped 190.91% in 2022 and soared 63.57% in 2024, its largest moves.
• Tracing ANIP's Non Operating Income over 5 years: stood at -$7.5 million in 2022, then gained by 23.45% to -$5.7 million in 2023, then fell by 4.68% to -$6.0 million in 2024, then advanced by 26.67% to -$4.4 million in 2025, then increased by 14.55% to -$3.8 million in 2026.
• Business Quant data shows ANIP's Non Operating Income at -$3.8 million in Q1 2026, -$4.4 million in Q4 2025, and -$4.7 million in Q3 2025.